American Association for Cancer Research
10780432ccr123505-sup-tab1.xlsx (240.37 kB)

Supplementary Table 1 from Discovery and Prevalidation of Salivary Extracellular microRNA Biomarkers Panel for the Noninvasive Detection of Benign and Malignant Parotid Gland Tumors

Download (240.37 kB)
posted on 2023-03-31, 17:47 authored by Johannes H. Matse, Janice Yoshizawa, Xiaoyan Wang, David Elashoff, Jan G.M. Bolscher, Enno C.I. Veerman, Elisabeth Bloemena, David T.W. Wong

XLSX file - 240K, Average Ct and average ΔCt values from the discovery phase. In the discovery phase, the expression of miRNAs in whole saliva from patients with a malignant parotid gland tumor (n=10) were compared to the expression of miRNAs in whole saliva from patients with a benign parotid gland tumor (n=10).



Purpose: This study was conducted to explore the differences in salivary microRNA (miRNA) profiles between patients with malignant or benign parotid gland tumors as a potential preoperative diagnostic tool of tumors in the salivary glands.Experimental Design: Whole saliva samples from patients with malignant (n = 38) or benign (n = 29) parotid gland tumors were obtained from the Salivary Gland Tumor Biorepository (SGTB). After total RNA isolation, human miRNA cards were used for miRNA profiling. The differential miRNA expression was analyzed using two-sided Wilcoxon test. Quantitative real-time PCR (qRT-PCR) was used to validate selected miRNAs in an independent sample set. Receiver-operating characteristics curve and probability of malignancy was exploited to evaluate the diagnostic power of the validated miRNAs.Results: With miRNA profiling, 57 of 750 investigated miRNAs were differently expressed, of which 54 showed higher miRNA expression in samples from patients with malignant tumors than those from patients with benign tumors. Validating the expression in an independent sample set of 9 miRNAs revealed indeed higher expression of miRNAs in malignant samples compared with benign samples. The expression of 6 validated miRNAs was statistically significantly different between the two groups (P < 0.05). A four miRNA combination was able to discriminate between saliva samples from patients with malignant tumors from those of patients with benign parotid gland tumors (sensitivity 69%, specificity 95%).Conclusions: Salivary miRNA profiles differ in saliva from patients with malignant from saliva from patients with a benign parotid gland tumor. These preliminary results are promising to develop a noninvasive diagnostic tool for diagnosing tumors in the salivary glands. Clin Cancer Res; 19(11); 3032–8. ©2013 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager